Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level

Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients

This study is designed in order to investigate the effect of cinacalcet in combination with routine conventional medical management for treatment of secondary hyperparathyroidism (SHPT) and Ca, P control. This study will compare the efficacy of a cinacalcet-based regimen with unrestricted conventional care (vitamin D and phosphate binders) for achieving the stringent National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) targets for dialysis patients.

Inclusion Criteria:

• Peritoneal dialysis patients with secondary HPT(iPTH > 300 pg/mL)
• > 18 yr of age, < 70
• had receive PD for > 3 mo,
• intact PTH level > 300 pg/ml and <1000 pg/ml
• albumin corrected Ca level >= 9.0 mg/dL

Exclusion Criteria:

• pregnant or breast-feeding,
• had undergone parathyroidectomy within previous 3 mo,
• are involved in other clinical trial within 30 d
• had received cinacalcet therapy previously.